Inovio Pharmaceuticals Inc (INO), Alnylam Pharmaceuticals, Inc. (ALNY): This Company Is in a Perfect Position to Take-off

Page 2 of 2

Other gainers last week

Many other companies also experienced gains last week. One of them was Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), which went up more than 18% last week. This orphan drug maker is enjoying revenue from its first and only FDA-approved drug, Solaris. Other than that, the company’s pipeline is filled with other drugs in clinical trials or discovery phases, which are giving positive results. According to rumors, after analyzing the current performance and the future growth potential of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), pharmaceutical giant Roche, is taking interest in buying out the company.

More good news came from the much smaller Inovio Pharmaceuticals Inc (NYSEMKT:INO), which has rallied 115% in the last month. On July 8, Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported that its H7N9 DNA vaccine component protected 100% of the vaccinated animals in clinical trials. Then, after just two days, Inovio Pharmaceuticals Inc (NYSEMKT:INO) reported that its next-generation Pennvax-B HIV vaccine combined with Cellectra improved the effectiveness in a Phase I study. Though the positive results of Inovio Pharmaceuticals Inc (NYSEMKT:INO) are encouraging, you should still be a bit cautious before investing in Inovio Pharmaceuticals Inc (NYSEMKT:INO) as it has a history of generating nothing more than losses for 30 years.

Final assessment

More and more investors are pouring money into this highly risky industry. So, to minimize risk, I would advise them to go for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as it has more growth to offer even after its recent surge.

The article This Company Is in a Perfect Position to Take-off originally appeared on Fool.com and is written by usman iftikhar.

usman iftikhar has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. usman is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2